Black Duck Appoints Sean Forkan as Chief Revenue Officer
Seasoned cybersecurity executive looks to accelerate revenue growth for newly independent application security leader.
"Sean joins us at a pivotal moment in Black Duck history as we launch the newly independent company with growth momentum, solid profitability, and a strong market position," said Jason Schmitt, Chief Executive Officer at Black Duck. "I am excited to partner with Sean as a team builder and customer champion to capitalize on this unique opportunity to match his impressive track record with our broad portfolio and growing market. Black Duck has emerged with a strong direct sales foundation, a mature global partner program, and a rapidly growing SaaS platform, which together offer the potential for even better growth and transformative value in our customers' software security programs."
About Black Duck
Black Duck®, formerly known as the Synopsys Software Integrity Group, offers the most comprehensive, powerful, and trusted portfolio of application security solutions in the industry. We have an unmatched track record of helping organizations around the world secure their software quickly, integrate security efficiently in their development environments, and safely innovate with new technologies. As the recognized leaders, experts, and innovators in software security, Black Duck has everything you need to build trust in your software. Learn more at www.blackduck.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/black-duck-appoints-sean-forkan-as-chief-revenue-officer-302300662.html
SOURCE Black Duck Software
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- QuintessenceLabs Introduces TSF® Sentry Cryptographic Assessment and PQC Readiness Assessment at Quantum World Congress
- Constellation Cold Logistics ("Constellation") announced today the appointment of Abhy Maharaj as Chief Executive Officer
- Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share